TIMP1 and neoplasm: It has been found that the combination of recombinant TIMP-1-GPI could improve the prognosis of fibrosarcoma patients by inhibiting the growth of fibrosarcoma as well as effectively increasing tumor sensitivity to doxorubicin (41), suggesting a future interest in optimizing the clinical management of fibrosarcoma patients by modulating the tumor microenvironment and thus enhancing the chemosensitivity of the tumor.